Sanofi (SNY +0.5%) discontinues Phase III trials of its atrial fibrillation drug Multaq, leaving...

|By:, SA News Editor

Sanofi (SNY +0.5%) discontinues Phase III trials of its atrial fibrillation drug Multaq, leaving competitor Cardiome's (CRME +2.5%) own recently approved oral antiarrhythmic Vernakalant open to gain market share.